Bosh sahifaMOLN • NASDAQ
add
Molecular Partners AG
Yopilish kursi
6,78 $
Kunlik diapazon
6,23 $ - 7,60 $
Yillik diapazon
3,32 $ - 12,70 $
Bozor kapitalizatsiyasi
234,39 mln USD
Oʻrtacha hajm
20,79 ming
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(CHF) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 1,55 mln | 273,73% |
Joriy xarajat | 4,44 mln | -4,84% |
Sof foyda | -15,08 mln | 5,66% |
Sof foyda marjasi | -972,40 | 74,76% |
Har bir ulushga tushum | — | — |
EBITDA | -15,37 mln | -0,62% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
(CHF) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 159,13 mln | -27,07% |
Jami aktivlari | 170,62 mln | -25,98% |
Jami passivlari | 15,05 mln | -38,62% |
Umumiy kapital | 155,57 mln | — |
Tarqatilgan aksiyalar | 33,18 mln | — |
Narxi/balansdagi bahosi | 1,45 | — |
Aktivlardan daromad | -22,42% | — |
Kapitaldan daromad | -24,17% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(CHF) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -15,08 mln | 5,66% |
Operatsiyalardan naqd pul | -15,72 mln | -18,38% |
Sarmoyadan naqd pul | 13,15 mln | 225,87% |
Moliyadan naqd pul | -267,00 ming | 2,55% |
Naqd pulning sof oʻzgarishi | -2,66 mln | 75,12% |
Boʻsh pul | -9,80 mln | -15,75% |
Haqida
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Tashkil etilgan
2004
Xodimlar soni
162